Scienture provides commercial update on Arbli

Scienture (SCNX) provided a commercial update on Arbli oral suspension, the first and only FDA-approved ready-to-use oral liquid formulation of losartan, alongside key market access achievements, financial strengthening initiatives, and near-term outlook-including reaffirming its plan to commercially launch Rezenopy, a life-saving opioid overdose emergency treatment, in the second quarter of 2026. Over the past four months, Scienture has executed a series of commercial, payer and patient-focused initiatives designed to materially expand access to Arbli across retail, institutional, and managed care channels within the approximately $241 million in total annual sales and 72 million prescriptions U.S. losartan market.